Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Jiangsu Topcel)
- Development stage
- Unknown
- Lead developer
- Jiangsu Topcel-KH Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Local Injection
01
Overview
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are an allogeneic cell therapy developed by Jiangsu Topcel Biotechnology in collaboration with KH Pharmaceutical. This specific cell product is being investigated for the prevention of arteriovenous fistula (AVF) stenosis, particularly in patients with end-stage diabetic kidney disease. AVF is the gold standard for hemodialysis access, but its utility is limited by high rates of stenosis caused by neointimal hyperplasia and chronic inflammation. The hUC-MSCs are administered via local injection at the anastomosis site during or after surgery. They function by secreting a variety of paracrine factors, including growth factors and anti-inflammatory cytokines, which modulate the local immune response, inhibit the proliferation of vascular smooth muscle cells, and promote the regeneration of the endothelial lining. This multi-targeted approach aims to maintain the patency of the fistula and reduce the need for re-intervention.
- Other names
- hUC-MSChuman umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Jiangsu Topcel).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Jiangsu Topcel).